Mofetilmikofenolat Tillomed (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mofetilmikofenolat Tillomed, is an antimetabolite presented as an oral formulation for oral use. It is employed to prevent organ transplant rejection and to treat certain autoimmune kidney disorders in adult patients.

GNH USA supplies Mofetilmikofenolat Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil is used in the management of immune‑mediated conditions where suppression of lymphocyte activity is required. - Organ transplant rejection (kidney, heart, liver): helps prevent acute and chronic graft rejection. - Lupus nephritis: reduces renal inflammation and proteinuria in systemic lupus erythematosus. - Certain autoimmune diseases (e.g., vasculitis, dermatomyositis): controls disease activity by limiting immune cell proliferation.

Mycophenolate Mofetil may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting - Diarrhea or abdominal pain - Headache - Tremor or dizziness - Hypertension - Upper respiratory tract infection

Serious or Rare Side Effects: - Bone marrow suppression (leukopenia, anemia, thrombocytopenia) - Opportunistic infections (e.g., CMV, PCP) - Increased risk of malignancy (skin cancers, lymphomas) - Hepatic toxicity (elevated transaminases, hepatitis) - Severe allergic reactions (rash, Stevens‑Johnson syndrome) - Pregnancy‑related teratogenicity (category X).

Patients receiving Mycophenolate Mofetil should be monitored closely for safety concerns. - Blood counts: monitor complete blood count regularly to detect marrow suppression. - Renal function: assess serum creatinine and glomerular filtration rate before and during therapy. - Pregnancy: contraindicated; ensure effective contraception for women of child‑bearing potential. - Drug interactions: avoid concomitant use with live vaccines and other potent immunosuppressants. - Dose adjustments: consider renal impairment when determining the prescribed dose. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mycophenolate Mofetil can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Live attenuated vaccines: may cause severe infection. - Azathioprine or cyclophosphamide: additive bone‑marrow toxicity. - Cholestyramine or colestipol: reduces drug absorption.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may decrease bioavailability. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase plasma levels. - NSAIDs: may exacerbate renal impairment. - ACE inhibitors or ARBs: heightened risk of hyperkalemia when combined with renal dysfunction.